OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Srour on the Safety and Efficacy of the Allogeneic CAR T-Cell Therapy CTX130 in Advanced ccRCC

April 9th 2024

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.

Dr Gopal on Treatment Selection in Second-Line R/R mUC

April 8th 2024

Nikhil A. Gopal, MD, discusses treatment selection in second-line relapsed/ refractory metastatic urothelial cancer.

Dr Thaker on the RAMP-301 Trial of Avutometinib/Defactinib in Low-Grade Serous Ovarian Cancer

April 8th 2024

Premal Thaker, MD, MS, discusses the phase 3 RAMP-301 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

Dr Patel-Donnelly on Factors Influencing Consolidation Therapy in Hematologic Malignancies

April 8th 2024

Dipti Patel-Donnelly, MD, discusses key factors to consider when selecting consolidation therapies in high-risk hematologic malignancies.

Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer

April 8th 2024

Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.

Dr Richardson on the UPLIFT Trial of Upifitamab Rilsodotin in Ovarian Cancer

April 8th 2024

Debra L. Richardson, MD, FACS, FACOG, discusses outcomes seen with upifitamab rilsodotin in the phase 1/2 UPLIFT trial for patients with ovarian cancer.

Dr Wong on Atezolizumab After Definitive Local Therapy in High-Risk HNSCC

April 8th 2024

Deborah J. Wong, MD, PhD, discusses the evaluation of atezolizumab vs placebo after definitive local therapy in high-risk, locally advanced HNSCC.

Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant

April 8th 2024

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

Dr Usmani on the FDA Approval of Cilta-Cel for Relapsed/Refractory Multiple Myeloma

April 6th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the FDA approval of cilta-cel for relapsed/refractory multiple myeloma.

Dr Obeng-Gyasi on Breast Cancer Mortality Rates in Resource-Poor Neighborhoods

April 6th 2024

Samilia Obeng-Gyasi, MD, MPH, discusses breast cancer mortality rates in resource-poor neighborhoods.

Dr Kenderian on the Efficacy of Liso-Cel in R/R CLL/SLL

April 6th 2024

Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.

Dr Chudgar on Defining Resectability in NSCLC

April 6th 2024

Neel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.

Dr Xu on Ongoing Biomarker Research in Metastatic RCC

April 5th 2024

Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.

Dr Dima on Real-World Responses With Teclistamab in R/R Multiple Myeloma

April 5th 2024

Danai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.

Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLC

April 5th 2024

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

Dr Kristeleit on 3-Year Follow-up Data for Rucaparib Maintenance in Ovarian Cancer

April 5th 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, on efficacy outcomes from the 3-year follow-up for patients with advanced ovarian cancer in the ATHENA-MONO study.

Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal Cancer

April 5th 2024

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

Dr Coombs on Noncovalent BTK Inhibitors in Relapsed/Refractory MCL

April 5th 2024

Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Dr Patel on the FDA Approval of Ide-Cel for Triple Class–Exposed R/R Multiple Myeloma

April 5th 2024

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

Dr Grivas on Future Directions for Adjuvant Therapy Research in RCC

April 4th 2024

Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.